ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0501 • ACR Convergence 2024

    How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)

    Delphine Sophie Courvoisier1, Yacine Mrad1, Denis Mongin1, Romain Aymon2, Roberto Caporali3, Denis Choquette4, Catalin Codreanu5, Louis Coupal4, Doreen Huschek6, Kimme Hyrich7, Florenzo Iannone8, Tore K. Kvien9, Monika Mustak10, Dan Nordstrom11, Nina Trokovic12, Lucia Otero-Varela13, Karel Pavelka14, Manuel Enrique Pombo Suarez15, Sella A. Provan16, Ana Maria Rodrigues17, Ziga Rotar18, Prodromos Sidiropoulos19, Anja Strangfeld20, Jakub Závada14, Sizheng Zhao21, Axel Finckh1 and Kim Lauper1, 1Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 4Rhumadata™, Montreal, QC, Canada, 5University of Medicine and Pharmacy, Bucharest, Romania, 6German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, 7Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 8Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, 11Helsinki University Hospital, Helsinki, Finland, 12Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, 13Spanish Society of Rheumatology, Madrid, Spain, 14Institute of Rheumatology and Charles University, Praha, Czech Republic, 15Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 16Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 17Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, 18University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 19University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, 20German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, 21Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom

    Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
  • Abstract Number: 0517 • ACR Convergence 2024

    Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

    Ji-Won Kim1, Ju-Yang Jung2, Chang-Hee Suh3 and Hyoun-Ah Kim1, 1Ajou university school of medicine, Suwon, South Korea, 2Ajou University of medical school, Suwon, South Korea, 3Ajou University Hospital, Suwon, South Korea

    Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
  • Abstract Number: 0535 • ACR Convergence 2024

    Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients

    Pauline Bovens1, Luuk Van Esveld2, Maike Wientjes1, Noortje van Herwaarden3, David Ten Cate4, Eward Melis3, Nienke Lesuis5, Bart van den Bemt6 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Sint Maartenskliniek, Utrecht, Netherlands, 3Sint Maartenskliniek, Nijmegen, Netherlands, 4Sint Maartenskliniek, Rotterdam, Netherlands, 5Hospital Group Twente, Almelo, Netherlands, 6Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands

    Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
  • Abstract Number: 0853 • ACR Convergence 2024

    Lung Ultrasound in Rheumatoid Arthritis and Systemic Sclerosis: Accuracy of B-line and Pleural Assessment

    Jesús Loarce1, Ana García de Vicente1, Javier Arechavala Hita1, Carlos de La Puente Bujidos1, Juan Rigual1, Francisco Javier Bachiller Corral2 and Mónica Vázquez Díaz1, 1Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 2Ramon y Cajal University Hospital, Madrid, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a frequent and severe complication of rheumatoid arthritis (RA) and systemic sclerosis (SSc). Although computerized tomography (CT) is considered…
  • Abstract Number: 0927 • ACR Convergence 2024

    Synovial Macrophage Heterogeneity and Dynamics in Steady Stateand Rheumatoid Arthritis Mouse Model Time Course

    Jessica Maciuch1, Yidan Wang2, Tyler Therron3, Harris Perlman1 and Deborah Winter4, 1Northwestern University, Chicago, IL, 2Northwestern University, Hanover Park, IL, 3Northwestern University, Chicago, 4Northwestern University, Skokie, IL

    Background/Purpose: Macrophages are vital contributors to both pro-inflammatory signaling and tissue repair processes involved in the pathogenesis and remission of Rheumatoid Arthritis (RA). Recent research…
  • Abstract Number: 0976 • ACR Convergence 2024

    Assessment of Current Trends in Demographic and Clinical Characteristics of Male Patients with Rheumatoid Arthritis in North India

    BHARAT KUMAR SINGH1 and Seema Singh2, 1CK Birla Hospitals, Jaipur, JAIPUR, Rajasthan, India, 2RAJASTHAN UNIVERSITY OF HEALTH SCIENCES, JAIPUR, Rajasthan, India

    Background/Purpose: Gender differences in rheumatoid arthritis (RA) are well-established, with women more prone to developing RA than men. However, understanding the impact of gender on…
  • Abstract Number: 1024 • ACR Convergence 2024

    Increased Social Vulnerability Index Predicts Lower Likelihood of Remission in Rheumatoid Arthritis Patients

    Daniel Montes1, Elena Myasoedova1, Chanakya Kodishala1, Roslin Jose George1, Andrew C. Hanson2, Vanessa Kronzer1, John Davis1 and Cynthia Crowson1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester

    Background/Purpose: Adverse social determinants of health (SDoH) are associated with poorer short- and long-term health outcomes. Prior studies have reported considerable prevalence of adverse SDoH…
  • Abstract Number: 1173 • ACR Convergence 2024

    Safety of Non-Exercise Rehabilitation Interventions for Adults with Rheumatoid Arthritis

    Megna Mishra1, Joshua Torrey2, Bria Dunn2 and Louise Thoma3, 1UNC Health, Cary, 2University of North Carolina-Chapel Hill, Chapel Hill, 3University of North Carolina, Chapel Hill, NC

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory condition. Improved outcomes occur with early diagnosis, evaluation, and management. Management includes pharmacological, exercise, rehabilitation, diet,…
  • Abstract Number: 1333 • ACR Convergence 2024

    Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study

    Orit Schieir1, Marie-France Valois2, Gilles Boire3, Louis Bessette4, Carter Thorne5, Susan Bartlett2, Glen Hazlewood6, Carol Hitchon7, Diane Tin5, Hugues Allard-Chamard8, Bindee Kuriya9, Janet Pope10 and Vivian Bykerk11, and on behalf of CATCH Investigators, 1McGill University, Montreal, QC, Canada, 2Centre for Outcomes Research & Eval, Montreal, QC, Canada, 3Retired, Sherbrooke, QC, Canada, 4University of Laval, Quebec City, QC, Canada, 5Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8University of Sherbrooke, Sherbrooke, QC, Canada, 9University of Toronto, Toronto, Canada, 10University of Western Ontario, London, ON, Canada, 11Hospital For Special Surgery, New York, NY

    Background/Purpose: Despite advances in early RA diagnosis and therapies, treatment outcomes can still vary considerably. Our objective was to compare short and long-term disease control…
  • Abstract Number: 1349 • ACR Convergence 2024

    Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis

    Jasmine Sim1, Nandhini Ramamoorthi2, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Anna Guttman4, Andrew Melville5, Nisha Rathore2, Stefan Siebert5, Iain McInnes6, Carl Goodyear5, Catharien Hilkens1, Andrew Filer7, Karim Raza7, Christopher Buckley8, Arthur Pratt1, James Wason9, Amy Anderson1, Michael Townsend2, Kenneth Baker1 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Genentech, South San Francisco, CA, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4Genentech, South San Franscisco, CA, 5School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 6University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 7Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 8Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 9Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
  • Abstract Number: 1365 • ACR Convergence 2024

    Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings

    Hui Yu1, Puran Nepal2, Laura Daniel3, Marco Barbero Mota4, Gul Karakoc5, Maria Carpintero1, C. Michael Stein6, Cecilia P. Chung1, Yan Guo1 and Vivian K. Kawai6, 1University of MIami, Miami, FL, 2Vanderbilt University Medical Center, Vanderbilt, TN, 3University of Miami, Nashville, TN, 4Vanderbilt University, Nashville, TN, 5Vanderbilt University Medical Center, Mt. Pleasant, SC, 6Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is a multisystem disease with a strong genetic component and multiple comorbidities. Genome wide association studies (GWAS) have identified single nucleotide…
  • Abstract Number: 1382 • ACR Convergence 2024

    Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis

    Yangsu Ren1, Catherine Aversa1, Myles Lewis2, Cankut Cubuk3, Felice Rivellese4, Liliane Fossati-Jimack3, Pejman Soroosh1, Amy Archer1, Martin Dahl1, Paul Lizzul1, Cailin Sibley1 and Costantino Pitzalis5, 1AnaptysBio, San Diego, CA, 2Queen Mary University of London, London, United Kingdom, 3Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, 4Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, 5QMUL, Bromley Kent, United Kingdom

    Background/Purpose: Despite multiple approved therapies in rheumatoid arthritis (RA), many patients do not achieve clinically meaningful responses, emphasizing the need for novel therapeutics with improved…
  • Abstract Number: 1398 • ACR Convergence 2024

    Difficult to Treat Rheumatoid Arthritis Incidence and Risk Factors in the Early Arthritis UCLouvain Brussels Cohort

    NATALUCCI Francesco1, Clément triaille2, SAPART Emilie3, DIERCKX Stéphanie4, VAN MULLEM Cécile3, de MONTJOYE Stéphanie3, SOKOLOVA Tatiana3, AVRAMOVSKA Aleksandra3 and DUREZ Patrick3, 1Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, 2Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, 3Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 4Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Bruxelles, Belgium

    Background/Purpose: Over the past decades, the treatment of Rheumatoid Arthritis (RA) has significantly improved, making accessible therapeutic goals such as clinical and structural remission. However,…
  • Abstract Number: 1677 • ACR Convergence 2024

    Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial

    Ru Li1, Xing Sun1, Suping Niu2, Xiaolin Sun1, Guimin Zheng3, Meilu Liu3, Jiyang Lv4, Gengmin Zhou4, Gang Yuan5, Yujin Ye5, Shuang Wang5, Pingfei Fang6, Qi Tang6, Jin Kang6, Xiaoyue Li7, Chao Sun7, Song Zhang7, Yongjun Mei7, Jian Wang7, He Su7, Lijing Huang8, Chenhui Li8, Chao Liu8, Fengxiao Zhang3, Qingwen Wang4, Niansheng Yang5, Fen Li6, Linjie Chen7, Yi Fang2 and Zhanguo Li9, 1Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 2Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, 3Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), 4Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), 5Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), 6Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), 7Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 8Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), 9Peking univeristy people's hospital, Beijing, China

    Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
  • Abstract Number: 1748 • ACR Convergence 2024

    Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level

    Rachel Elam1, Emma Kersey2, Jing Li3, Gabriela Schmajuk4 and Laura Carbone5, 1Augusta University, Evans, GA, 2University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5Augusta University, Augusta, GA

    Background/Purpose: Fracture incidence rates (IRs) are higher in men and women with rheumatoid arthritis (RA) than those without RA, especially for those with higher RA…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology